| Objective:Systemic lupus erythematosus(SLE) patients diagnosed newly and visited regularly in Provincial hospital affiliated to shandong universital from January 2010 to January 2015 were studied to compare the clinical results, laboratory results’ changes and SLEDAI of SLE patients with anti-SSA/Ro52 Antibodies--prior and post-treatment, and to investigate the significance in the pathogenesis, diagnosis andtreatment, prognosis of SLE.Participants and Methods:216 SLE patients diagnosed newly and visited regularly in Provincial hospital affiliated to shandong universital from January 2010 to January 2015 were studied prospectively, which include 108 SLE patients with anti-SSA/Ro52 antiboies and 108 patients without anti-SSA/Ro52. By comparing the clinical features, laboratory results、SLEDAI、system damage quantity before treatment,3 months and 6 months after treatment in the two groups. In addition, prior-treatment and post-treatment were compared in two groups respectively. The data is analyzed by SPSS 19.0 software. Measurement data is indicated using an independent samples t-test (data of two groups has homogeneity of variance), count data is analysed by chi-square test, ranked data is made using rank sum test. P< 0.05 is regarded to indicate statistical significance.Results:1. Comparing the patients without anti-SSA/Ro52, facia discoid rash, dry eyes, Raynaud’s phenomenon, SS were significantly higher in patients with anti-SSA/ Ro52 before treatment (P<0.05 or 0.01). After 3 months, Raynaud’s phenomeno n-. symptoms of dry mouth recovering difficultly were significantly higher in pa tients with anti-SSA/Ro52 (P<0.05 or 0.01), but there is no significant differen ce in other clinical manifestations(P>0.05). After 6 months, there is no differen ce in clinical manifestations between the two groups.2. Compared with pretherapy, the disc type erythema, hand rash, photosensitivit y, mouth sores and hair loss, arthritis, dry mouth, dry eyes, Raynaud’s phenom enon, fever, lupus nephritis are improved significantly in the two groups respec tively after 3 and 6 months, differences in the clinical performance are no sign ificant statistically comparing prior treatment with post-treatment (P< 0.01), th e effect is more obvious after 6 months. There are no differences in clinical m anifestations comparing treatment of 3 months with treatment of 6 months. The remission rate of clinical symptoms has no difference significantly in two gro ups.3. In patients with anti-SSA/Ro52 antibodies before treatment, anti-rRNP、anti-SSB、 high IgG are significantly higher than these in the patients without anti-SSA/Ro52 (P<0.05 or 0.01). After 3 months, anti-rRNP、high IgG were significantly higher in patients with anti-SSA/Ro52 antibodies(P<0.05 or 0.01). After 6 months, anti-ds-DNA、anti-rRNP、high IgG in the anti-SSA/Ro52 antibody-positive group were higher than those in the anti-SSA/Ro52 antibody-negative group(P<0.05), but there is no significant difference in other Laboratory indexes(P>0.05).4. After treatment, the two groups were significantly improved in laboratory indicators respectively. Compared with pretherapy, laboratory indicators appear improved significantly in the two groups respectively after 3 and 6 months(P<0.01), and comparing the treatment of 6 months with the treatment of 3 months, the anti-ds-DNA, Auna, AHA of the negative group were statistically significant (P<0.01). After 6 months, remission rate of the negative group was significantly higher in high IgG, C4 decreased, anti-ds-DNA and Anua positive (P<0.01 or 0.05).5. The SLEDAI has no difference in two groups before treatment and after 3 months respectively(P>0.05). But after 6 months, there was significant difference in SLE disease activity index (DAI) in the two groups, and there was higher SLEDAI in the anti-SSA/Ro52 antibody-positive group (P<0.05. System damage quantity has no difference in two groups before and after treatment(P>0.05).Conclusion:1. Anti-SSA/Ro52 antibody has important relationship with clinical feature. The positive group was more likely to have facial discoid rash, dry eyes, Raynau d’s phenomenon, SS. Moreover, the antibody may affect recovery of SLE patie nts with Raynaud’s phenomenon, dry mouth, which has great significance to th e pathogenesis and control of disease in SLE patients.2. Anti-SSA/Ro52 antibody is one of the important anbody-indexes of SLE pat ients’serum. The patients with positive antibody has some laboratory features a nd anti-rRNP, anti-SSB, high IgG are higher significantly. After 6 months, the positive group has higher positive rate of anti-dsDNA antibody, and in the neg ative group, the remission rate of IgG increased, C4 decreased, and the positiv e anti-dsDNA was obvious.3. After 6 months, there was higher SLEDAI in the anti-SSA/Ro52 antibody-positive group, suggesting that anti-SSA/Ro52 antibody is associated with disease activity, which may affect the recovery rate of SLE. It is speculated that anti-SSA/Ro52 antibodies are closely related to the pathogenesis and prognosis of SLE. |
PDF Full Text Request